Edited By Uwe Marx And Volker Sandig. Includes Bibliographical References And Index. Also Available In An Electronic Version. Mode Of Access: World Wide Web.
Recent trends in cell substrate considerations for continuous cell lines: Commentary
β Scribed by Anthony S Lubiniecki; John C Petricciani
- Publisher
- Elsevier Science
- Year
- 2001
- Tongue
- English
- Weight
- 37 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0958-1669
No coin nor oath required. For personal study only.
β¦ Synopsis
Product development activity in the past five to ten years has reconstituted a version of an old debate on the safety assessment of biological products, namely whether the use of some types of continuous cell lines (CCLs) is appropriate in the preparation of some types of biological products. Since 1987, dozens of purified recombinant DNA products derived from CCLs have been developed and have received regulatory approval. In addition, several live attenuated and inactivated viral vaccines manufactured in CCLs were approved after thorough review of product safety and manufacturing issues. The current discussion revolves around the potential use of CCLs (human or not) to prepare purified protein subunit vaccines, such as for HIV, and the use of human CCLs to prepare purified protein products.
Addresses *GlaxoSmithKline R&D,
π SIMILAR VOLUMES
Edited By Uwe Marx And Volker Sandig. Includes Bibliographical References And Index. Also Available In An Electronic Version. Mode Of Access: World Wide Web.
DSD-1-PG is a chondroitin sulfate proteoglycan with neurite-outgrowth promoting properties expressed during development and upon lesion of neural tissues which has been defined with the specific monoclonal antibody 473HD. Double immunofluorescence studies performed on primary cerebellar cultures doc